Form 4 Tracker
Scott L Burrows

Chief Financial Officer · 9 filings · Latest: Sep 30, 2026

Spyre Therapeutics, Inc.
TickerOwnerRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Filing
SYRE
Scott L BurrowsChief Financial OfficerOct 1, 2026
Sale
$91.837,500$688.8K79,762
SYRE
Scott L BurrowsChief Financial OfficerOct 1, 2026
Option Exercise
$14.507,500$108.8K87,262
SYRE
Scott L BurrowsChief Financial OfficerSep 30, 2026
Sale
$89.8917,500$1.6M79,762
SYRE
Scott L BurrowsChief Financial OfficerSep 30, 2026
Option Exercise
$14.5017,500$253.8K97,262
SYRE
SCOTT BURROWS—Sep 30, 2026
Proposed Sale
$89.8917,500$1.6M—
SYRE
Scott L BurrowsChief Financial OfficerSep 2, 2026
Sale
$89.3518,232$1.6M79,762
SYRE
Scott L BurrowsChief Financial OfficerSep 1, 2026
Sale
$87.317,500$654.8K97,994
SYRE
Scott L BurrowsChief Financial OfficerSep 1, 2026
Option Exercise
$14.507,500$108.8K105,494
SYRE
Scott L BurrowsChief Financial OfficerAug 3, 2026
Sale
$95.577,500$716.8K97,994
SYRE
Scott L BurrowsChief Financial OfficerAug 3, 2026
Option Exercise
$14.507,500$108.8K105,494
SYRE
SCOTT BURROWS—Aug 3, 2026
Proposed Sale
$98.3330,000$2.9M—
SYRE
Scott L BurrowsChief Financial OfficerJul 1, 2026
Sale
$87.747,500$658.0K97,994
SYRE
Scott L BurrowsChief Financial OfficerJul 1, 2026
Option Exercise
$14.507,500$108.8K105,494
SYRE
Scott L BurrowsChief Financial OfficerJun 25, 2026
Sale
$87.1315,000$1.3M97,994
SYRE
Scott L BurrowsChief Financial OfficerJun 25, 2026
Option Exercise
$14.5015,000$217.5K112,994
SYRE
SCOTT BURROWS—Jun 25, 2026
Proposed Sale
$87.1315,000$1.3M—
SYRE
Scott L BurrowsChief Financial OfficerJun 1, 2026
Sale
$71.067,500$532.9K97,994
SYRE
Scott L BurrowsChief Financial OfficerJun 1, 2026
Option Exercise
$14.507,500$108.8K105,494
SYRE
Scott L BurrowsChief Financial OfficerMay 1, 2026
Sale
$71.3712,500$892.1K97,994
SYRE
Scott L BurrowsChief Financial OfficerMay 1, 2026
Option Exercise
$14.5012,500$181.3K110,494

Page 1 of 2

Next →